10-Q: Dare Bioscience Reports Q2 Loss, Secures Funding

Dare Bioscience, a women's health biopharmaceutical company, reported a significant net loss and cash burn in Q2 2025, raising going concern doubts, but has secured substantial post-period capital and grant funding.

Summary

• Net loss of $8.4 million for the six months ended June 30, 2025, compared to net income of $6.2 million in the prior year period.
• Cash and cash equivalents decreased to $5.0 million as of June 30, 2025, from $15.7 million at December 31, 2024.
• Net cash used in operating activities was $10.9 million for the six months ended June 30, 2025, a significant increase from cash provided by operations of $6.1 million in the prior year.
• Working capital deficit of approximately $12.6 million as of June 30, 2025.
• Accumulated deficit reached approximately $183.7 million.
• Substantial doubt exists about the company's ability to continue as a going concern within the next 12 months.
• Post-period, the company raised approximately $17.6 million net from ATM stock sales and received $6.0 million in grant funding.
• Research and development expenses decreased by 55% to $3.7 million for the six months ended June 30, 2025, primarily due to increased contra R&D expenses from grant funding.
• Ovaprene Phase 3 study enrollment is ongoing, but completion is not expected in 2025.
• Initiation of Sildenafil Cream Phase 3 study is delayed beyond 2025 due to FDA feedback.
• Company regained compliance with Nasdaq's stockholders' equity rule but is subject to a one-year mandatory monitoring period.
• Expanding business strategy to include Section 503B compounding (DARE to PLAY Sildenafil Cream targeting Q4 2025 revenue) and consumer health products.

Sentiment

Score: 4

Explanation: The company faces significant financial challenges, including substantial losses, cash burn, and a going concern doubt. Key clinical trials are experiencing delays. While post-period capital raises and grant funding provide a temporary reprieve and Nasdaq compliance was achieved, the underlying financial instability and development setbacks warrant a cautious outlook. The dual-path strategy is innovative but unproven in terms of material revenue generation in the near term.

Positives

• Secured approximately $17.6 million in net proceeds from ATM stock sales in July 2025, significantly mitigating near-term liquidity risk.
• Received an additional $6.0 million payment from the Gates Foundation for the DARE-LARC1 program in July 2025.
• Regained compliance with Nasdaq's stockholders' equity listing requirement on July 24, 2025.
• Ovaprene Phase 3 study's Data Safety Monitoring Board (DSMB) recommended continuation without modification, identifying no new safety or tolerability concerns.
• Expansion of business strategy to include Section 503B compounding and consumer health products offers new potential revenue streams.
• Significant non-dilutive grant funding continues to support key R&D programs like DARE-LARC1, Ovaprene, and DARE-HPV.

Negatives

• Reported a net loss of $8.4 million for the six months ended June 30, 2025, a significant decline from net income in the prior year period.
• Experienced a substantial decrease in cash and cash equivalents, from $15.7 million at December 31, 2024, to $5.0 million at June 30, 2025.
• Shifted to negative cash flow from operations, using $10.9 million for the six months ended June 30, 2025, compared to providing $6.1 million in the prior year.
• Accumulated deficit increased to approximately $183.7 million, and the company has a working capital deficit of $12.6 million.
• Substantial doubt exists about the company's ability to continue as a going concern within the next 12 months.
• Ovaprene Phase 3 study enrollment is not expected to be completed in 2025, and the company cannot reasonably predict the completion time.
• Initiation of the Sildenafil Cream Phase 3 study is delayed beyond 2025 due to additional FDA input and information requests.
• Nasdaq compliance is subject to a one-year mandatory panel monitor, increasing delisting risk if non-compliant again.
• Royalty revenue was negative for the three months ended June 30, 2025, due to an adjustment for lower actual royalty revenue than previously estimated.

Risks

• Inability to raise additional capital under favorable terms or at all, or generate sufficient revenue from new business strategies to fund operating needs and continue as a going concern.
• Dependence on grants and other financial awards from governmental entities and a private foundation, with uncertainty regarding future funding (e.g., NIH budget).
• Inexperience and lack of infrastructure for commercializing products, particularly for Section 503B compounding and consumer health products.
• Reliance on third parties for operating plan execution, commercialization, and clinical studies, with risks of delays or difficulties in agreements and performance.
• Difficulties or delays in commencement or completion, or termination/suspension, of current or planned clinical or preclinical studies (e.g., Ovaprene enrollment, Sildenafil Cream Phase 3 initiation).
• Failure to complete development or obtain FDA/foreign regulatory approval for product candidates on projected timelines or budgets.
• Challenges and delays in obtaining timely supplies of product candidates.
• Potential removal of bulk drug substances from FDA's 503B compounding list.
• Changes in laws or regulations related to compounded drugs under Section 503B or consumer health products.
• Termination by collaborators of out-license agreements (e.g., Organon for XACIATO, Bayer for Ovaprene).
• Unfavorable or unanticipated macroeconomic factors, geopolitical events, public health emergencies, or natural disasters affecting business and capital raising.
• Weak interest in women's health from the investment community or potential collaborators.
• Cyber-attacks, security breaches, or similar events.
• Difficulty introducing branded products in a market with generic competition.
• Inability to adequately protect or enforce intellectual property rights.
• Lack of patent protection for active ingredients in some products, exposing them to competition.
• Higher risk of failure for preclinical product candidates.
• Fluctuations in operating results or results differing from investor expectations.
• Failure to maintain Nasdaq listing, especially during the one-year mandatory panel monitor period where delisting risk is heightened.
• Development of safety, efficacy, or quality concerns related to products.
• Product liability claims or governmental investigations.
• Changes in government laws and regulations affecting the business.
• Increased costs and management time due to public company operations and compliance.

Future Outlook

The company plans to focus on the ongoing Ovaprene Phase 3 study, executing its Section 503B compounding and consumer health product strategies (targeting DARE to PLAY Sildenafil Cream revenue in Q4 2025 and DARE-HRT1 in late 2026), and advancing grant-funded programs like DARE-LARC1 and DARE-HPV. Engagement with the FDA for Sildenafil Cream Phase 3 and development of other clinical/preclinical programs will continue. Operating expenses are expected to increase substantially as development progresses and new business strategies expand.

Management Comments

• Our mission is to accelerate innovation in women's health by advancing evidence-based solutions that address decades of unmet needs.
• We believe innovation in women's health does not always have to start from scratch it can also come from rethinking how and when innovation reaches women.
• We regularly hear from healthcare providers, researchers, and women themselves about the urgent need for expanded access to evidenced-based and convenient options.
• Our goal is to fulfill that need by bringing innovative products to market as soon as practicable whether as FDA-approved therapies or through alternative regulatory pathways that enable earlier availability, such as Section 503B compounding.
• We do not believe Section 503B compounding will impact the regulatory process or commercial opportunity for an FDA-approved product utilizing the same proprietary formulation.
• We are taking action to bring our proprietary topical cream formulation of sildenafil to market under Section 503B. The compounded drug will be branded as DARE to PLAY Sildenafil Cream.
• We are also taking action to bring DARE-HRT1 to market under 503B.

Industry Context

The company operates in the women's health biopharmaceutical sector, which is experiencing growing awareness around menopause, sexual health, and vaginal health, leading to a shift in conversation and demand for evidence-based solutions. The company's dual-path strategy, combining traditional FDA approval pathways with Section 503B compounding, aims to address the urgent need for timely access to treatments, differentiating itself by leveraging alternative regulatory pathways for earlier market entry. This approach positions the company to potentially capitalize on immediate market demand while pursuing long-term value creation through FDA approvals, in an industry often characterized by lengthy and costly development cycles.

Comparison to Industry Standards

• The company's strategy of leveraging Section 503B compounding for earlier market access, as seen with DARE to PLAY Sildenafil Cream and DARE-HRT1, is a notable deviation from the traditional biopharmaceutical model focused solely on FDA approval. This could provide a competitive advantage in terms of speed to market and initial revenue generation compared to peers relying exclusively on lengthy clinical trial and regulatory processes.
• The significant reliance on non-dilutive grant funding from entities like the Gates Foundation and NIH/NICHD for programs such as DARE-LARC1, Ovaprene, and DARE-HPV is a strong positive, reducing the capital burden typically seen in early-stage biopharma development. This contrasts with many smaller biotechs that rely almost entirely on equity financing.
• The reported net loss and substantial cash burn are common for clinical-stage biopharmaceutical companies, but the "going concern" doubt highlights a more acute financial challenge compared to well-capitalized industry leaders. The post-period capital raises are critical for mitigating this, but the ongoing need for capital is a standard industry challenge.
• Delays in pivotal Phase 3 trials (Ovaprene, Sildenafil Cream) are common in drug development, but they extend time-to-market and increase costs, potentially impacting the company's competitive position against other companies developing women's health solutions.

Corporate Governance

Related Party Transactions

• Consulting agreement with former Chief Financial Officer, effective January 26, 2024, for a nine-month period, paying $31,667 per month plus up to $500 per month for health insurance premiums.

Stakeholder Impact

• Shareholders: Face substantial dilution risk from ongoing and future equity raises. The "going concern" doubt and potential Nasdaq delisting pose significant risks to investment value. However, post-period capital raises provide some stability.
• Employees: Continued R&D activities and new business strategies indicate ongoing operations, but financial instability and potential need to "delay, scale back or eliminate" programs could impact job security. Stock-based compensation is a component of their remuneration.
• Customers/Patients: Potential for earlier access to proprietary formulations through Section 503B compounding (e.g., DARE to PLAY Sildenafil Cream, DARE-HRT1) addresses unmet needs and offers new treatment options. Delays in FDA-approved product development could impact long-term availability.
• Creditors: The "going concern" doubt and working capital deficit indicate increased credit risk. The security interest granted to XOMA on certain product assets affects collateral.
• Licensors/Collaborators: Continued grant funding and strategic agreements are positive for partners. Delays in clinical trials could impact milestone payments and commercialization timelines for partners like Bayer.

Next Steps

• Continue ongoing Ovaprene Phase 3 study enrollment.
• Execute Section 503B compounding business strategy, focusing on DARE to PLAY Sildenafil Cream (targeting Q4 2025 availability) and DARE-HRT1 (targeting late 2026 availability).
• Advance consumer health products, starting with vaginal probiotics after DARE to PLAY Sildenafil Cream launch.
• Advance grant-funded development programs, particularly DARE-LARC1 and DARE-HPV.
• Continue engagement with the FDA to align on the Phase 3 program for Sildenafil Cream.
• Evaluate and pursue various capital raising options, including equity sales, debt financings, grants, collaborations, and strategic transactions.
• Monitor Nasdaq compliance, especially during the one-year mandatory panel monitor period.

Key Dates

Recommendation

While the company faces significant financial headwinds, including a substantial net loss, negative cash flow from operations, and a stated 'going concern' doubt, it has successfully secured critical capital post-period through equity sales and grant funding, which provides a near-term lifeline. The dual-path strategy for commercialization (FDA approval alongside Section 503B compounding) is an interesting approach to accelerate market access and potential revenue. However, delays in key clinical programs (Ovaprene, Sildenafil Cream) and the ongoing need for substantial additional capital introduce considerable uncertainty and risk. The Nasdaq compliance, while positive, comes with a strict monitoring period. Given the high risk profile, but also the recent capital infusion and strategic initiatives, a 'hold' recommendation is appropriate for investors who are already exposed and can tolerate high risk, awaiting clearer signs of financial stability and clinical/commercial progress. New investors should exercise extreme caution.

Keywords

Women's Health, Biopharmaceutical, SEC Filing, 10-Q, Clinical Trials, FDA Approval, Section 503B Compounding, Ovaprene, Sildenafil Cream, DARE-HRT1, DARE-HPV, DARE-LARC1, XACIATO, Contraception, Sexual Health, Vaginal Health, Menopause, Financial Results, Going Concern, Capital Raise, Nasdaq Listing, Grant Funding, Biotech